Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Dechend, R; Fiebler, A; Lindschau, C; Bischoff, H; Muller, D; Park, JK; Dietz, R; Haller, H; Luft, FC
   Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition
   AMERICAN JOURNAL OF HYPERTENSION
   
   R. Dechend et al., "Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition", AM J HYPERT, 14(6), 2001, pp. 55S-61S
2. Muller, DN; Heissmeyer, V; Dechend, R; Hampich, F; Park, JK; Fiebeler, A; Shagdarsuren, E; Theuer, J; Elger, M; Pilz, B; Breu, V; Schroer, K; Ganten, D; Dietz, R; Haller, H; Scheidereit, C; Luft, FC
   Aspirin inhibits NF-kappa B and protects from angiotensin II-induced organdamage
   FASEB JOURNAL
   
   D.N. Muller et al., "Aspirin inhibits NF-kappa B and protects from angiotensin II-induced organdamage", FASEB J, 15(8), 2001, pp. NIL_117-NIL_135
3. Fiebeler, A; Schmidt, F; Muller, DN; Park, JK; Dechend, R; Bieringer, M; Shagdarsuren, E; Breu, V; Haller, H; Luft, FC
   Mineralocorticoid receptor affects AP-1 and nuclear factor-kappa B activation in angiotensin II-Induced cardiac injury
   HYPERTENSION
   
   A. Fiebeler et al., "Mineralocorticoid receptor affects AP-1 and nuclear factor-kappa B activation in angiotensin II-Induced cardiac injury", HYPERTENSIO, 37(2), 2001, pp. 787-793
4. Dechend, R; Fiebeler, A; Park, JK; Muller, DN; Theuer, J; Mervaala, E; Bieringer, M; Gulba, D; Dietz, R; Luft, FC; Haller, H
   Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
   CIRCULATION
   
   R. Dechend et al., "Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor", CIRCULATION, 104(5), 2001, pp. 576-581
5. Witowski, J; Thiel, A; Dechend, R; Dunkel, K; Fouquet, N; Bender, TO; Langrehr, JM; Gahl, GM; Frei, U; Jorres, A
   Synthesis of C-X-C and C-C chemokines by human peritoneal fibroblasts - Induction by macrophage-derived cytokines
   AMERICAN JOURNAL OF PATHOLOGY
   
   J. Witowski et al., "Synthesis of C-X-C and C-C chemokines by human peritoneal fibroblasts - Induction by macrophage-derived cytokines", AM J PATH, 158(4), 2001, pp. 1441-1450
6. Muller, DN; Mervaala, EMA; Schmidt, F; Park, JK; Dechend, R; Genersch, E; Breu, V; Loffler, BM; Ganten, D; Schneider, W; Haller, H; Luft, FC
   Effect of bosentan on NF-kappa B, inflammation, and tissue factor in angiotensin II-induced end-organ damage
   HYPERTENSION
   
   D.N. Muller et al., "Effect of bosentan on NF-kappa B, inflammation, and tissue factor in angiotensin II-induced end-organ damage", HYPERTENSIO, 36(2), 2000, pp. 282-290
7. Muller, DN; Dechend, R; Mervaala, EMA; Park, JK; Schmidt, F; Fiebeler, A; Theuer, J; Breu, V; Ganten, D; Haller, H; Luft, FC
   NF-kappa B inhibition ameliorates angiotensin II-induced inflammatory damage in rats
   HYPERTENSION
   
   D.N. Muller et al., "NF-kappa B inhibition ameliorates angiotensin II-induced inflammatory damage in rats", HYPERTENSIO, 35(1), 2000, pp. 193-201
8. Mervaala, E; Muller, DN; Park, JK; Dechend, R; Schmidt, F; Fiebeler, A; Bieringer, M; Breu, V; Ganten, D; Haller, H; Luft, FC
   Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes
   HYPERTENSION
   
   E. Mervaala et al., "Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes", HYPERTENSIO, 35(1), 2000, pp. 360-366
9. Park, JK; Muller, DN; Mervaala, EMA; Dechend, R; Fiebeler, A; Schmidt, F; Bieringer, M; Schafer, O; Lindschau, C; Schneider, W; Ganten, D; Luft, FC; Haller, H
   Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects
   KIDNEY INTERNATIONAL
   
   J.K. Park et al., "Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects", KIDNEY INT, 58(4), 2000, pp. 1420-1430
10. Dechend, R; Homuth, V; Wallukat, G; Kreuzer, J; Park, JK; Theuer, J; Juepner, A; Gulba, DC; Mackman, N; Haller, H; Luft, FC
    AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor
    CIRCULATION
    
    R. Dechend et al., "AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor", CIRCULATION, 101(20), 2000, pp. 2382-2387
11. Muller, DN; Mervaala, EMA; Dechend, R; Fiebeler, A; Park, JK; Schmidt, F; Theuer, J; Breu, V; Mackman, N; Luther, T; Schneider, W; Gulba, D; Ganten, D; Haller, H; Luft, FC
    Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor inangiotensin II-induced cardiac vasculopathy
    AMERICAN JOURNAL OF PATHOLOGY
    
    D.N. Muller et al., "Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor inangiotensin II-induced cardiac vasculopathy", AM J PATH, 157(1), 2000, pp. 111-122
12. Dechend, R; Hirano, F; Lehmann, K; Heissmeyer, V; Ansieau, S; Wulczyn, FG; Scheidereit, C; Leutz, A
    The Bcl-3 oncoprotein acts as a bridging factor between NF-kappa B/Rel andnuclear co-regulators
    ONCOGENE
    
    R. Dechend et al., "The Bcl-3 oncoprotein acts as a bridging factor between NF-kappa B/Rel andnuclear co-regulators", ONCOGENE, 18(22), 1999, pp. 3316-3323
13. Luft, FC; Mervaala, E; Muller, DN; Gross, V; Schmidt, F; Park, JK; Schmitz, C; Lippoldt, A; Breu, V; Dechend, R; Dragun, D; Schneider, W; Ganten, D; Haller, H
    Hypertension-induced end-organ damage - A new transgenic approach to an old problem
    HYPERTENSION
    
    F.C. Luft et al., "Hypertension-induced end-organ damage - A new transgenic approach to an old problem", HYPERTENSIO, 33(1), 1999, pp. 212-218
14. Dechend, R; Maass, M; Gieffers, J; Dietz, R; Scheidereit, C; Leutz, A; Gulba, DC
    Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappa B and induces tissue factor and PAI-1 expression - A potential link to accelerated arteriosclerosis
    CIRCULATION
    
    R. Dechend et al., "Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappa B and induces tissue factor and PAI-1 expression - A potential link to accelerated arteriosclerosis", CIRCULATION, 100(13), 1999, pp. 1369-1373
15. GULBA DC; PRAUS M; DECHEND R; HAUCK S; MAHLER M; ZITVZ R; BALDUS B; MULLER W; DIETZ R
    UPDATE ON THE TOXICOLOGY AND PHARMACOLOGY OF RDSPA ALPHA-1 (BAT-PA) IN ANIMALS AND HUMANS
    Fibrinolysis & proteolysis
    
    D.C. Gulba et al., "UPDATE ON THE TOXICOLOGY AND PHARMACOLOGY OF RDSPA ALPHA-1 (BAT-PA) IN ANIMALS AND HUMANS", Fibrinolysis & proteolysis, 11, 1997, pp. 55-62
16. ANSIEAU S; KOWENZLEUTZ E; DECHEND R; LEUTZ A
    B-MYB, A REPRESSED TRANSACTIVATING PROTEIN
    Journal of molecular medicine
    
    S. Ansieau et al., "B-MYB, A REPRESSED TRANSACTIVATING PROTEIN", Journal of molecular medicine, 75(11-12), 1997, pp. 815-819
17. GULBA DC; TANSWELL P; DECHEND R; SOSADA M; WEIS A; WAIGAND J; UHLICH F; HAUCK S; JOST S; RAFFLENBEUL W; LICHTLEN PR; DIETZ R
    60-MINUTE ALTEPLASE PROTOCOL - A NEW ACCELERATED RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR REGIMEN FOR THROMBOLYSIS IN ACUTE MYOCARDIAL-INFARCTION
    Journal of the American College of Cardiology
    
    D.C. Gulba et al., "60-MINUTE ALTEPLASE PROTOCOL - A NEW ACCELERATED RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR REGIMEN FOR THROMBOLYSIS IN ACUTE MYOCARDIAL-INFARCTION", Journal of the American College of Cardiology, 30(7), 1997, pp. 1611-1617
18. GROSS CM; KRAMER J; WAIGAND J; UHLICH F; SCHRODER G; THALHAMMER C; DECHEND R; GULBA DC; DIETZ R
    STENT IMPLANTATION IN PATIENTS WITH SUPERIOR VENA-CAVA SYNDROME
    American journal of roentgenology
    
    C.M. Gross et al., "STENT IMPLANTATION IN PATIENTS WITH SUPERIOR VENA-CAVA SYNDROME", American journal of roentgenology, 169(2), 1997, pp. 429-432
19. SIMOONS ML; RUTSCH W; VAHANIAN A; ADGEY J; MASERI A; VASSANELLI C; COL J; ADELMAN A; MACAYA C; MILLER H; DEBOER MJ; MCCLOSKEY R; WEISMAN H; VERSTRAETE M; DEBONO D; SWEDBERG K; LESSAFRE E; SCHOTSMANS P; TIJSSEN J; BAR F; DECKERS JW; PIEK JJ; KLOOTWIJK APJ; BLOCK P; CATS VM; BRUGGELING W; JONKMAN F; VANDERMEER P; UMANS V; FOLEY D; ANSINK T; KEANE D; SANE D; KOUDSTAAL P; VANDENBRAND MJBM; LAARMAN GJ; HENDRICKX G; DESCHEERDER I; STEG PG; BEATT K; VANPAPENDRECHT MH; LENDERINK T; MALBRAIN S; PAUL J; DECRAEN T; CABACOWIC S; SCHAIBLE T; ANDERSON K; WANG A; FITZPATRICK S; DANIELS M; POULUSSEN T; DEGRAFF J; DIJKHUIZEN M; VERHAMME K; NELISSEN I; GIBBS M; MARRON S; LOCHU S; GUIOT C; FERRARI P; VIZZOTTO A; ALEMANY A; MALTILLO E; HOFFMANN S; STAHL L; KAFKA D; SURYAPRANATA H; LIEM AL; VELSINK G; VANDERWIEKEN R; EZECHIELS JP; ZONNEVELD S; VANDENBRAND M; VANDERZWAAN C; KINT PP; MICHELS RM; BONMIER J; VANDERKERKHOF I; HANEKAMP C; PEELS J; DROK L; DENHEIJER P; PLOKKER T; MAST EG; MARQUEZ K; VANDENBOS AA; CHIN U; CORNEL JH; ARNOLD A; GARBARZ E; NALLET O; FARRAH B; CARRIE D; PUEL J; JEAN M; CHARBONNIER B; PACOURET G; RAYNAUD R; BERTRAND B; VANZETTO G; GROLLIER G; VALETTE B; THERY C; LABLANCHE JM; DUCLOS F; COSTE P; BEAUFILS P; EIFERMAN E; DAUBERT C; LECLERCQ C; JULIARD JJM; BASSAND JP; MENEVEAU N; GUERMONPREZ JL; VROLIX M; VANLIERDE J; JACOBS S; BOLAND J; SAAT G; BAUMANS P; STAELENS F; DEBRUYNE B; TAEYMANS Y; GHEERAERT P; ALSCHWAFI K; VANDENHEUVEL P; ROGIERS R; CASTADOT M; DEWIT E; GULBA D; DECHEND R; CHRISTOW S; SIMON R; ALMOKTHARI N; VONDAHL J; JANSSENS U; HAUDE M; BAUMGART D; KARSCH KR; MAIER R; BRUNCKHORST C; REIFART N; KRAJCAR M; RUPPRECHT HJ; COBAUGH M; HERNANDEZANTOLIN R; SEGOVIA J; GARCIA P; CEQUIR A; ESPLUGAS E; GOMEZHOSPITAL J; MAURI J; ANGEL J; BALLESTER R; DELATASSA CM; BARRIALES F; AUGE J; GARCIA J; MELGARES R; KHAN M; JOHNSTON P; MCKAY Y; BEEN M; KAHN A; ILSLEY C; EWAN A; REID D; MCDERMOTT A; WARD D; BULLER N; BALCON R; ZARDINI P; LOSCHIAVO I; CASARI A; PITI A; COSTALUNGA A; REPETTO S; CARELLA S; MARZILLI M; FEDELE S; CHIOIN R; REIMERS B; MAZZARI A; SPECCHIA G; CHIARIELLO M; SHEPPS D; SCLAROVSKI S; GAL B; CASPI A; AYZENBERG O; SHARIR T; HOD H; BUSER P; PFISTERER M; RITZ R; BERTEL O; ROHNER F; DUCAS J; SHICK U; CHEUNG P; CHISHOLM R; COHEN E; GOMEZ RS; FERREIRA J; MUHLBERGER V
    RANDOMIZED PLACEBO-CONTROLLED TRIAL OF ABCIXIMAB BEFORE AND DURING CORONARY INTERVENTION IN REFRACTORY UNSTABLE ANGINA - THE CAPTURE STUDY
    Lancet
    
    M.L. Simoons et al., "RANDOMIZED PLACEBO-CONTROLLED TRIAL OF ABCIXIMAB BEFORE AND DURING CORONARY INTERVENTION IN REFRACTORY UNSTABLE ANGINA - THE CAPTURE STUDY", Lancet, 349(9063), 1997, pp. 1429-1435
20. DECHEND R; MO X; SCHULZ W; GROSS M; PRAUS M; DIETZ R; GULBA DC
    THROMBIN RECEPTOR AND UROKINASE-TYPE PLASMINOGEN-ACTIVATOR ARE COLOCALIZED IN VASCULAR SMOOTH-MUSCLE CELLS DERIVED FROM HUMAN CAROTID ATHEROSCLEROTIC PLAQUES
    Fibrinolysis
    
    R. Dechend et al., "THROMBIN RECEPTOR AND UROKINASE-TYPE PLASMINOGEN-ACTIVATOR ARE COLOCALIZED IN VASCULAR SMOOTH-MUSCLE CELLS DERIVED FROM HUMAN CAROTID ATHEROSCLEROTIC PLAQUES", Fibrinolysis, 10, 1996, pp. 41-45
21. GULBA DC; GROSS M; DECHEND R; LUFT F; SOSADA M; FREY U; DIETZ R
    THROMBOLYTIC THERAPY IN RENAL ARTERIAL EM BOLISM - CASE-REPORT WITH LITERATURE-REVIEW
    Der Internist
    
    D.C. Gulba et al., "THROMBOLYTIC THERAPY IN RENAL ARTERIAL EM BOLISM - CASE-REPORT WITH LITERATURE-REVIEW", Der Internist, 37(6), 1996, pp. 623-627
22. MO XM; DECHEND R; KOWENZLEUTZ E; DIETZ R; LEUTZ A; GULBA DC
    DOSE-DEPENDENT INHIBITION OF APOPTOSIS OF HUMAN AORTIC SMOOTH-MUSCLE CELLS (HASMC) BY ANTIOXIDANTS
    Circulation
    
    X.M. Mo et al., "DOSE-DEPENDENT INHIBITION OF APOPTOSIS OF HUMAN AORTIC SMOOTH-MUSCLE CELLS (HASMC) BY ANTIOXIDANTS", Circulation, 94(8), 1996, pp. 905-905
23. FRIEDRICH MG; DECHEND R; BARKOWSKI A; JUNGNICKEL K; BACHER P; WELZEL D; DIETZ R; GULBA DC
    PREVENTION OF RESTENOSIS AFTER PTCA WITH LONG-TERM TREATMENT OF LOW-MOLECULAR-WEIGHT HEPARIN - RESULTS OF A PILOT-STUDY
    Thrombosis and haemostasis
    
    M.G. Friedrich et al., "PREVENTION OF RESTENOSIS AFTER PTCA WITH LONG-TERM TREATMENT OF LOW-MOLECULAR-WEIGHT HEPARIN - RESULTS OF A PILOT-STUDY", Thrombosis and haemostasis, 73(6), 1995, pp. 981-981
24. DECHEND R; SELBIG D; PRAUS M; HAUCK S; DIETZ R; GULBA DC
    LONG-TERM THROMBOLYTIC THERAPY WITH 2 NEW RT-PA REGIMEN IN SUBMASSIVEPULMONARY-EMBOLISM - RESULTS OF A PILOT-STUDY
    Thrombosis and haemostasis
    
    R. Dechend et al., "LONG-TERM THROMBOLYTIC THERAPY WITH 2 NEW RT-PA REGIMEN IN SUBMASSIVEPULMONARY-EMBOLISM - RESULTS OF A PILOT-STUDY", Thrombosis and haemostasis, 73(6), 1995, pp. 1108-1108
25. GULBA DC; DECHEND R; FRIEDRICH MG; FRIEDRICH M; DIETZ R; LUFT FC
    THROMBOLYTIC THERAPY IN RENAL ARTERIAL EMBOLISM
    Thrombosis and haemostasis
    
    D.C. Gulba et al., "THROMBOLYTIC THERAPY IN RENAL ARTERIAL EMBOLISM", Thrombosis and haemostasis, 73(6), 1995, pp. 1328-1328
26. DECHEND R; GULBA DC; HAUCK S; DIETZ R
    THE PROBLEM OF REOCCLUSION AND RESTENOSIS - CLINICAL ASPECTS
    Fibrinolysis
    
    R. Dechend et al., "THE PROBLEM OF REOCCLUSION AND RESTENOSIS - CLINICAL ASPECTS", Fibrinolysis, 9, 1995, pp. 48-52
27. HAUCK S; FRIEDRICH M; DECHEND R; GULBA DC; DIETZ R
    CONTINUOUS 3-DIMENSIONAL VECTORCARDIOGRAPHY, A VALUABLE TOOL FOR ONLINE ISCHEMIA MONITORING
    Fibrinolysis
    
    S. Hauck et al., "CONTINUOUS 3-DIMENSIONAL VECTORCARDIOGRAPHY, A VALUABLE TOOL FOR ONLINE ISCHEMIA MONITORING", Fibrinolysis, 9, 1995, pp. 114-120
28. PRAUS M; MO XM; GROSSE Y; BALDUS B; MORSER J; DECHEND R; GULBA DC
    A NOVEL THROMBOMODULIN BASED PLASMA ASSAY UNCOVERS ABNORMALITIES IN THE PROTEIN-S PROTEIN-C ANTICOAGULANT PATHWAY DISTINCT FROM RESISTANCE TO ACTIVATED PROTEIN-C IN MYOCARDIAL-INFARCTION PATIENTS
    Circulation
    
    M. Praus et al., "A NOVEL THROMBOMODULIN BASED PLASMA ASSAY UNCOVERS ABNORMALITIES IN THE PROTEIN-S PROTEIN-C ANTICOAGULANT PATHWAY DISTINCT FROM RESISTANCE TO ACTIVATED PROTEIN-C IN MYOCARDIAL-INFARCTION PATIENTS", Circulation, 92(8), 1995, pp. 2989-2989
29. GULBA DC; DECHEND R
    THROMBOLYSIS IN THROMBOEMBOLIC DISEASES
    Annals of hematology
    
    D.C. Gulba e R. Dechend, "THROMBOLYSIS IN THROMBOEMBOLIC DISEASES", Annals of hematology, 69(4), 1994, pp. 190000041-190000057
30. DECHEND R; HAUCK S; EICHHORN J; GOEDECKE W; PRAUS M; SCHULZMENGER J; BARTHELS M; DIETZ R; GULBA DC
    EFFECTS OF LOW-MOLECULAR-WEIGHT AND HIGH-MOLECULAR-WEIGHT HEPARIN ON THE INTRINSIC AND EXTRINSIC ENDOGENOUS FIBRINOLYTIC SYSTEM
    Fibrinolysis
    
    R. Dechend et al., "EFFECTS OF LOW-MOLECULAR-WEIGHT AND HIGH-MOLECULAR-WEIGHT HEPARIN ON THE INTRINSIC AND EXTRINSIC ENDOGENOUS FIBRINOLYTIC SYSTEM", Fibrinolysis, 8, 1994, pp. 71-74
31. DECHEND R; THODE H; MULLER T; EISERT WE; DIETZ R; GULBA DC
    FRAGMENTATION-PATTERN OF FIBRINOGEN DURING THROMBOLYSIS IN ACUTE MYOCARDIAL-INFARCTION WITH FIBRIN-SPECIFIC PLASMINOGEN ACTIVATORS - DETECTION OF HIGH-MOLECULAR-WEIGHT FIBRINOGEN DEGRADATION PRODUCTS
    Fibrinolysis
    
    R. Dechend et al., "FRAGMENTATION-PATTERN OF FIBRINOGEN DURING THROMBOLYSIS IN ACUTE MYOCARDIAL-INFARCTION WITH FIBRIN-SPECIFIC PLASMINOGEN ACTIVATORS - DETECTION OF HIGH-MOLECULAR-WEIGHT FIBRINOGEN DEGRADATION PRODUCTS", Fibrinolysis, 8, 1994, pp. 102-104